Bristol-Myers Squibb Stock Forecast for 2022 - 2025 - 2030

Updated on 05/25/2022

Stock Rating
8 / 10
Price Target
$78.00
Consensus
Outperform
Upside
1.13%
Analysts
16
Stock Rating
8
Upside
1.13%
Analysts
16
Price Target
$78.00

If the average 2022 price target of $78.00 recently set by sixteen prominent experts for Bristol-Myers Squibb is met, there would be a potential upside of approximately 1.13% from the last closing price in May, 2022. The high estimate is $94.00, and the low is $63.00. If you're looking for information on Bristol-Myers Squibb stock, consider checking out the forecasts for comparable firms such as NasdaqGS:AMGN.

$78.00

1.13% Upside

Outperform
Outperform

Bristol-Myers Squibb Fair Value Forecast for 2022 - 2025 - 2030

In the past three years, Bristol-Myers Squibb's Fair Value has seen significant growth, rising from $48.28 to $91.10 – a growth of 88.69%. In the next year, analysts believe that Fair Value will reach an unimpressive $93.89 – an increase of 3.06%. By 2030, professionals predict that Bristol-Myers Squibb's Fair Value will decrease by 8.79%, to a mere $83.09.

2022 Fair Value Forecast
$93.89
2023 Fair Value Forecast
$99.83
2024 Fair Value Forecast
$103.23
2025 Fair Value Forecast
$107.84
2026 Fair Value Forecast
$103.47
2027 Fair Value Forecast
$100.07
2028 Fair Value Forecast
$96.19
2029 Fair Value Forecast
$88.06
2030 Fair Value Forecast
$83.09
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
JNJ Stock Forecast Johnson & Johnson Outperform 3
$181.40 $187.12 1.98% 16
PFE Stock Forecast Pfizer Outperform 7
$53.41 $58.26 2.98% 16
ROG Stock Forecast Roche Holding Outperform 3
CHF346.20 CHF384.23 12.94% 20
LLY Stock Forecast Eli Lilly and Outperform 5
$305.96 $281.95 4.92% 12
ABBV Stock Forecast AbbVie Outperform 6
$149.11 $152.52 12.5% 19

Bristol-Myers Squibb Revenue Forecast for 2022 - 2025 - 2030

In the past three years, Bristol-Myers Squibb's Revenue has seen significant growth, rising from $22.56B to $46.39B – a growth of 105.6%. In the next year, analysts believe that Revenue will reach an unimpressive $47.10B – an increase of 1.55%. By 2030, professionals predict that Bristol-Myers Squibb's Revenue will decrease by 20.45%, to a mere $36.90B.

2022 Rev Forecast
$47.10B
2023 Rev Forecast
$48.66B
2024 Rev Forecast
$50.13B
2025 Rev Forecast
$51.08B
2026 Rev Forecast
$49.48B
2027 Rev Forecast
$47.55B
2028 Rev Forecast
$43.96B
2029 Rev Forecast
$39.19B
2030 Rev Forecast
$36.90B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
NOVO B Stock Forecast Novo Nordisk A/S Hold 5
kr655.00 kr678.96 25.19% 11
MRK Stock Forecast Merck Outperform 6
$94.64 $91.73 0.38% 19
AZN Stock Forecast AstraZeneca PLC Outperform 3
£104.94 £136.08 39% 13

Bristol-Myers Squibb Dividend per Share Forecast for 2022 - 2025 - 2030

Bristol-Myers Squibb's DPS has seen considerable growth in the last three years, rising from $1.61 to $2.01 – a growth of 24.84%. In the next year, analysts believe that DPS will reach an unimpressive $2.13 – an increase of 5.97%. For the next nine years, experts predict that Bristol-Myers Squibb's DPS will grow at a rate of 4.48%.

2022 DPS Forecast
$2.13
2023 DPS Forecast
$2.25
2024 DPS Forecast
$2.37
2025 DPS Forecast
$2.44
2026 DPS Forecast
$2.45
2027 DPS Forecast
$2.10
2028 DPS Forecast
$2.10
2029 DPS Forecast
$2.10
2030 DPS Forecast
$2.10
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
NOVN Stock Forecast Novartis Outperform 7
CHF77.22 CHF103.75 19.24% 12
DHR Stock Forecast Danaher Outperform 5
$252.00 $339.17 32.94% 7
MDT Stock Forecast Medtronic Outperform 4
$105.59 $123.50 15.54% 5

Bristol-Myers Squibb Free Cash Flow Forecast for 2022 - 2025 - 2030

In the past three years, Bristol-Myers Squibb's Free Cash Flow has grown by 149.13%, rising from $6.12B to $15.23B. For the next year, analysts predict that Free Cash Flow will reach $20.19B – an increase of 32.5%. In 2030, professionals predict that Bristol-Myers Squibb's Free Cash Flow will decrease by 2.26%, reaching $14.89B.

2022 FCF Forecast
$20.19B
2023 FCF Forecast
$19.68B
2024 FCF Forecast
$19.61B
2025 FCF Forecast
$19.19B
2026 FCF Forecast
$19.10B
2027 FCF Forecast
$17.17B
2028 FCF Forecast
$16.36B
2029 FCF Forecast
$15.84B
2030 FCF Forecast
$14.89B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
SAN Stock Forecast Sanofi Outperform 3
102.30€ 104.66€ 11.88% 20
AMGN Stock Forecast Amgen Hold 6
$251.89 $246.46 -0.75% 13
GSK Stock Forecast GlaxoSmithKline Outperform 1
£17.64 £16.08 2.04% 11

Bristol-Myers Squibb Net Income Forecast for 2022 - 2025 - 2030

Bristol-Myers Squibb's Net Income has seen impressive growth in the last three years, rising from $4.92B to $6.99B – a growth of 42.15%. In the next year, analysts believe that Net Income will reach an impressive $16.50B – an increase of 135.92%. For the next nine years, the forecast is for Net Income to grow by 90.07%.

2022 NI Forecast
$16.50B
2023 NI Forecast
$17.26B
2024 NI Forecast
$17.43B
2025 NI Forecast
$17.87B
2026 NI Forecast
$17.08B
2027 NI Forecast
$16.55B
2028 NI Forecast
$15.67B
2029 NI Forecast
$14.22B
2030 NI Forecast
$13.29B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
MMM Stock Forecast 3M Hold 5
$145.75 $188.41 9.98% 17
GILD Stock Forecast Gilead Sciences Outperform 5
$64.35 $75.96 6.45% 19
MRK Stock Forecast MERCK Kommanditgesellschaft au... Outperform 2
172.40€ 147.51€ 21.81% 15

Bristol-Myers Squibb EBITDA Forecast for 2022 - 2025 - 2030

In the last three years, Bristol-Myers Squibb's EBITDA has seen significant growth, surging from $5.87B to $20.58B – an increase of 250.7%. In the next year, analysts predict that EBITDA will jump to $21.39B – up 3.95% from the current level. By 2030, professionals believe that Bristol-Myers Squibb's EBITDA will have decreased by an astonishing 32.53%, plummeting to just $13.89B.

2022 EBITDA Forecast
$21.39B
2023 EBITDA Forecast
$21.50B
2024 EBITDA Forecast
$21.76B
2025 EBITDA Forecast
$21.84B
2026 EBITDA Forecast
$22.73B
2027 EBITDA Forecast
$19.18B
2028 EBITDA Forecast
$18.16B
2029 EBITDA Forecast
$14.60B
2030 EBITDA Forecast
$13.89B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
REGN Stock Forecast Regeneron Pharmaceuticals Outperform 8
$686.02 $696.64 2.04% 14
BAYN Stock Forecast Bayer Outperform 5
63.29€ 67.79€ 20.08% 14
4519 Stock Forecast Chugai Pharmaceutical Hold 3
¥3.79k ¥0.00 18.73% 0

Bristol-Myers Squibb EBIT Forecast for 2022 - 2025 - 2030

In the past three years, Bristol-Myers Squibb's EBIT has seen a significant increase, rising from $5.28B to $9.82B. This represents a growth of 86.09%. Analysts predict that Bristol-Myers Squibb's EBIT will increase significantly in the upcoming year, reaching $19.38B. This would represent an increase of 97.33%. Over the next nine years, experts predict that Bristol-Myers Squibb's EBIT will grow at a rate of 54.9%

2022 EBIT Forecast
$19.38B
2023 EBIT Forecast
$20.34B
2024 EBIT Forecast
$20.77B
2025 EBIT Forecast
$21.43B
2026 EBIT Forecast
$20.31B
2027 EBIT Forecast
$19.04B
2028 EBIT Forecast
$18.30B
2029 EBIT Forecast
$16.43B
2030 EBIT Forecast
$15.21B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BAS Stock Forecast BASF Outperform 5
48.76€ 78.27€ 31.26% 16
ILMN Stock Forecast Illumina Outperform 3
$240.26 $376.81 45.68% 0
BAX Stock Forecast Baxter International Outperform 5
$73.90 $92.47 21.79% 3

Bristol-Myers Squibb EPS Price Prediction Forecast for 2022 - 2025 - 2030

In the past three years, Bristol-Myers Squibb's EPS has seen significant growth, rising from $3.98 to $7.51 – a growth of 88.69%. In the next year, analysts believe that EPS will reach an unimpressive $7.74 – an increase of 3.06%. By 2030, professionals predict that Bristol-Myers Squibb's EPS will decrease by 8.79%, to a mere $6.85.

2022 EPS Forecast
$7.74
2023 EPS Forecast
$8.23
2024 EPS Forecast
$8.51
2025 EPS Forecast
$8.89
2026 EPS Forecast
$8.53
2027 EPS Forecast
$8.25
2028 EPS Forecast
$7.93
2029 EPS Forecast
$7.26
2030 EPS Forecast
$6.85
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
A Stock Forecast Agilent Technologies Outperform 7
$124.41 $172.40 28.61% 2
BIIB Stock Forecast Biogen Outperform 4
$202.54 $287.21 12.32% 24
COLO B Stock Forecast Coloplast A/S Hold 3
kr929.20 kr1.05k 10.85% 13

© Copyright 2022 | Stock Forecast | All Rights Reserved